COVAXIN | Page 4 | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Sunday
May 25, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SUNDAY, MAY 25, 2025

COVAXIN

Reena Jani, 34, a health worker, receives the vaccine developed by Oxford/AstraZeneca at Mathalput Community Health Centre, during the coronavirus disease (Covid-19) pandemic, in Koraput, India, January 16, 2021. REUTERS/Danish Siddiqui
Coronavirus chronicle

From factory to faraway village: Behind India's mammoth vaccination drive

The 1.5 million vaccinated so far are a tiny first phase of a vaccine programme that India hopes will eventually protect its 1.4 billion people from the coronavirus

India to give homegrown vaccine in seven more states this week
Coronavirus chronicle

India to give homegrown vaccine in seven more states this week

Workers pack syringes at the Hindustan Syringes factory in Faridabad, India on Sept. 2, 2020. SAJJAD HUSSAIN/AFP/GETTY IMAGES
Analysis

India’s vaccine diplomacy

Representational image. Picture: Collected
Coronavirus chronicle

Bharat Biotech's Covid-19 shot safe, produced immune response in early human trial

Covaxin phase 1 trial clears Lancet review, phase 3 trial ongoing
Coronavirus chronicle

Covaxin phase 1 trial clears Lancet review, phase 3 trial ongoing

Indian Health Minister Harsh Vardhan holds a dose of Bharat Biotech's COVID-19 vaccine called Covaxin, during a vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India, January 16, 2021. REUTERS/Adnan Abidi
Covid-19 in Bangladesh

India's Bharat Biotech seeks Bangladesh trial for Covid vaccine approved at home

 Bharat Biotech completes volunteer enrollment for Phase 3 clinical trials
Coronavirus chronicle

Bharat Biotech completes volunteer enrollment for Phase 3 clinical trials

A medic fills a syringe with COVAXIN, an Indian government-backed experimental Covid-19 vaccine, before administering it to a health worker during its trials, at the Gujarat Medical Education and Research Society in Ahmedabad, November 26, 2020. REUTERS/Amit Dave/File Photo
Coronavirus chronicle

Criticism mounts over India's 'abrupt' approval of COVAXIN

India's approval of homegrown vaccine criticised over lack of data
Coronavirus chronicle

India's approval of homegrown vaccine criticised over lack of data

Covid-19 vaccines approved by India '110% safe' - DCGI chief
Coronavirus chronicle

Covid-19 vaccines approved by India '110% safe' - DCGI chief

A medic administers Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), during the Phase- 3 trials at the People's Medical College in Bhopal.(PTI)
Coronavirus chronicle

Indian expert panel recommends Bharat Biotech’s Covaxin for restricted emergency use

Indian Covid-19 vaccine Covaxin triggered immune response, finds Phase 1 trial
Coronavirus chronicle

Indian Covid-19 vaccine Covaxin triggered immune response, finds Phase 1 trial

India Biotech starts phase three clinical trials of Covaxin
Coronavirus chronicle

India Biotech starts phase three clinical trials of Covaxin

  • Show More
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net